ANI Pharmaceuticals, Inc. (ANIP) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $78.29. It has a SharesGrow Score of 70/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ANIP = $482.01 (+515.7% from the current price, the stock appears undervalued). Analyst consensus target is ANIP = $107 (+36.7% upside).
Valuation: ANIP trades at a trailing Price-to-Earnings (P/E) of 21 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.25.
Financials: revenue is $883M, +41.3%/yr average growth. Net income is $78M, growing at +154.5%/yr. Net profit margin is 8.9% (thin). Gross margin is 51% (-5.1 pp trend).
Balance sheet: total debt is $325M against $541M equity (Debt-to-Equity (D/E) ratio 0.6, moderate). Current ratio is 2.71 (strong liquidity). Debt-to-assets is 22.6%. Total assets: $1.4B.
Analyst outlook: 7 / 10 analysts rate ANIP as buy (70%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 67/100 (Partial), Moat 55/100 (Partial), Future 85/100 (Pass), Income 45/100 (Partial).
